# UCM Technologies — CA-62 Cancer Screening Test
# Full Content Version for AI/LLM Crawlers
# https://www.tryucm.com/llms-full.txt

This document contains the complete text content of the UCM Technologies CA-62 cancer screening website (tryucm.com) for use by AI language models, search engines, and automated systems.

---

## HOME PAGE (https://www.tryucm.com/)

### Hero Section

Headline: Detect Cancer Earlier. From the Comfort of Home.

The CA-62 blood test detects cancer signals with over 90% sensitivity at early stages — far surpassing leading competitors. Order online, a nurse visits your home, and your results arrive in 10 days.

Call to Action: Order Your CA-62 Test — $300 (No prescription required)

### Key Statistics

- >90% — Early-Stage Sensitivity (Stage I & II detection)
- $300 — Per Test (vs. $949 for Galleri)
- 10 days — To Results (Secure online delivery)
- 5,000+ — Samples Validated (Across North America)

### How It Works (3 Steps)

Step 1 — Order Online: Complete our secure online order form in minutes. No prescription or doctor's referral required. Choose your preferred appointment window and pay securely.

Step 2 — Nurse Visits Your Home (within 70–120 hours): A certified, background-checked nurse arrives at your home at the scheduled time. The blood draw takes under 10 minutes — identical to any routine blood test.

Step 3 — Receive Your Report (~10 days): Your comprehensive wellness report is delivered securely to your online account. Clear results, biomarker levels, and recommended next steps.

### Why Choose CA-62

1. Detect Cancer Earlier — CA-62 levels are highest during Stage I and II, making it uniquely effective at detecting cancer when it is most treatable. Over 90% sensitivity for early-stage epithelial cancers.

2. Universal Cancer Marker — Unlike organ-specific tests (PSA for prostate, CA-125 for ovarian), CA-62 is a universal epithelial cancer marker that screens for a broad range of cancers in one blood test.

3. Detects Pre-Cancerous Conditions — CA-62 can identify pre-cancerous conditions such as adenomatous polyps and prostate adenoma before they develop into cancer.

4. Completely At-Home — No clinic visits, no waiting rooms. A certified nurse comes to your home at a time that suits you. The entire process is designed around your convenience.

5. Affordable — At $300 all-inclusive, the CA-62 test is a fraction of the cost of competing multi-cancer early detection tests like Galleri ($949).

6. No Prescription Needed — Order directly online without a doctor's referral or prescription.

### Competitor Comparison Table

| Feature | CA-62 (UCM Technologies) | Galleri (GRAIL) | Cologuard (Exact Sciences) |
|---|---|---|---|
| Early-Stage Sensitivity | >90% | ~27.5% | N/A |
| Price | $300 | $949 | ~$649 |
| Prescription Required | No | Yes | No |
| At-Home Nurse Visit | Yes | No | No |
| Pre-cancerous Detection | Yes | No | Yes |
| Cancer Types | Multiple epithelial | 50+ types | Colorectal only |
| Results Timeline | ~10 days | ~2 weeks | ~2 weeks |

### The Science (Summary)

The CA-62 biomarker is a family of low-weight membrane transport N-glycoproteins that appear on the surface of poorly differentiated cells during malignant transformation. These glycoproteins circulate in the bloodstream and can be detected via a proprietary chemiluminescent immunoassay.

Pilot study results (1,005 asymptomatic participants):
- Sensitivity: 88–94% at 95% specificity
- Negative Predictive Value: 100%
- 11/11 cancers detected
- Pre-cancerous and inflammatory conditions also identified

Published in: ASCO Journal of Clinical Oncology (2023, 2024), Frontiers in Oncology (2023, 2025)

---

## HOW IT WORKS PAGE (https://www.tryucm.com/how-it-works)

### Step 1: Order Online (5 minutes)
Visit tryucm.com and complete a brief health questionnaire. No prescription or doctor's referral required. Choose your preferred nurse visit time window and complete your purchase securely for $300. Instant order confirmation via email.

### Step 2: Scheduling Confirmation (within 24 hours)
Our scheduling team will contact you within 24 hours of your order to confirm your nurse visit appointment. We work around your schedule to find a time that is most convenient for you. Flexible scheduling — morning, afternoon, or evening. Nurse visits within 70–120 hours of ordering.

### Step 3: Nurse Visits Your Home (70–120 hours after ordering)
A certified, professional nurse arrives at your home at the scheduled time. The blood draw is a simple, routine procedure — identical to any standard blood test — and typically takes under 10 minutes. The nurse is certified, background-checked, and trained in proper specimen collection. The sample is securely packaged and shipped to the laboratory.

### Step 4: Laboratory Analysis (Days 1–8 after blood draw)
Your blood sample is analyzed in a CLIA-certified, CAP-accredited laboratory using the proprietary CA-62 chemiluminescent immunoassay. The test measures the concentration of the CA-62 N-glycoprotein biomarker in your blood. Rigorous quality control is maintained at every step with full chain of custody.

### Step 5: Receive Your Report (~10 days after blood draw)
Your comprehensive wellness report is delivered securely to your online account. The report includes: your CA-62 biomarker levels, a clear positive/negative result with interpretation, detailed context, recommended follow-up actions, and the option to share with your physician.

### Quality Assurances
- CLIA-Certified Laboratory: All samples analyzed in CLIA-certified and CAP-accredited laboratory
- Certified Nurses: All home visit nurses are fully certified, background-checked, and trained
- Fast Turnaround: From order to results in approximately 10–14 days

---

## THE SCIENCE PAGE (https://www.tryucm.com/science)

### What is the CA-62 Biomarker?

CA-62 is a family of low-weight membrane transport N-glycoproteins that appear uniquely on the surface of poorly differentiated cells — including embryonic, stem, and cancer cells — during malignant transformation.

When epithelial cells undergo malignant transformation, they transform into pluripotent stem cells. The CA-62 glycoprotein appears on the surface of these cancer cells, enters the intracellular space, and then circulates in the bloodstream where it can be detected and quantified.

CA-62 levels are highest during the early stages of cancer, making it an exceptional tool for early detection — precisely when treatment is most effective.

Key distinction: Unlike many cancer biomarkers that are organ-specific (e.g., PSA for prostate, CA-125 for ovarian), CA-62 is a universal epithelial cancer marker — it detects a wide range of epithelial carcinomas from a single blood test.

### Pilot Study Results (1,005 Asymptomatic Participants)

- Total Participants: 1,005 (asymptomatic, age 45+)
- Sensitivity: 88–94% at 95% specificity
- Negative Predictive Value: 100% (zero false negatives in study)
- Cancers Detected: 11/11 (100% detection rate in study)

Cancer types detected in the study:
- B-cell lymphoma
- Sigmoid carcinoma
- Choroidal melanoma
- Acute leukemia
- Renal cell carcinoma
- Breast cancer (2 cases)
- Prostate cancer (2 cases)
- Endometrial carcinoma (2 cases)

Pre-cancerous conditions detected:
- Adenomatous polyps: 9 cases
- Prostate adenoma: 1 case

Inflammatory conditions detected:
- Acute GI disorders: 5 cases
- Hepatobiliary conditions: 4 cases
- Immune-mediated lung diseases (sarcoidosis-type): 3 cases

### Early-Stage Sensitivity Comparison

CA-62 (UCM Technologies): >90% early-stage sensitivity (Stage I & II)
Galleri (GRAIL): ~27.5% early-stage sensitivity (Source: The Lancet, 2024)

Why this matters: A cancer screening test must have high sensitivity for early-stage disease, where intervention is most likely to lead to a cure. A test that detects only 27.5% of early-stage cancers will miss the majority of cases when they are most treatable.

### Peer-Reviewed Publications

1. "A novel three-biomarker signature (CA-62, CEA, CYFRA 21-1) and early-stage NSC lung cancer detection" — ASCO Journal of Clinical Oncology, 2023. https://ascopubs.org/doi/10.1200/JCO.2023.41.16_suppl.3038

2. "CA-62: A new biomarker for the detection of early-stage renal cell carcinoma" — ASCO Journal of Clinical Oncology, 2024. https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.4526

3. "Clinical validation of the novel CLIA-CA-62 assay efficacy for early-stage breast cancer detection" — Frontiers in Oncology, 2023. https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2023.1009863/full

4. "Diagnostic significance of the novel biomarker combination for early-stage non-small cell lung cancer detection" — Frontiers in Oncology, 2025. https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2025.1508563/full

---

## ORDER PAGE (https://www.tryucm.com/order)

Price: $300 USD all-inclusive

What is included:
- CA-62 blood test analysis
- Certified nurse home visit (within 70–120 hours)
- CLIA-certified laboratory processing
- Secure online wellness report (~10 days)
- No hidden fees

Order process:
1. Enter personal information (name, email, phone, address)
2. Select preferred appointment window
3. Complete secure payment

---

## FAQ PAGE (https://www.tryucm.com/faq)

Q: What is the CA-62 test?
A: The CA-62 test is a blood-based cancer screening test that measures the concentration of the CA-62 N-glycoprotein biomarker in your blood. Elevated levels are associated with early-stage epithelial cancers, pre-cancerous conditions, and certain inflammatory conditions.

Q: What types of cancer can the CA-62 test detect?
A: CA-62 is a universal epithelial cancer marker. It has demonstrated the ability to detect breast, prostate, lung, colorectal, ovarian, endometrial, renal cell carcinoma, and other epithelial carcinomas. It can also detect pre-cancerous conditions such as adenomatous polyps.

Q: How accurate is the CA-62 test?
A: In a pilot study of 1,005 asymptomatic participants, the CA-62 test demonstrated sensitivity of 88–94% at 95% specificity, with a 100% negative predictive value. All 11 cancers present in the study population were detected.

Q: Is the CA-62 test FDA-approved?
A: The CA-62 test is currently a wellness screening tool and is not approved for diagnostic use by the FDA or Health Canada. It is designed to complement, not replace, standard cancer screening methods.

Q: How does CA-62 compare to Galleri (GRAIL)?
A: CA-62 demonstrates over 90% sensitivity for Stage I and II cancers, while Galleri has published early-stage sensitivity of approximately 27.5–37.3% (The Lancet, 2024). CA-62 is also significantly more affordable at $300 versus Galleri's $949, does not require a prescription, and also detects pre-cancerous conditions.

Q: Do I need a doctor's prescription?
A: No. The CA-62 test can be ordered directly online without a doctor's prescription or referral.

Q: When will the nurse visit me?
A: Our scheduling team contacts you within 24 hours of your order. The nurse visit takes place within 70–120 hours (approximately 3–5 days) of your order.

Q: How will I receive my results?
A: Results are delivered securely to your online account approximately 10 days after your blood draw.

Q: What does a positive result mean?
A: A positive result means elevated CA-62 levels were detected. This does not diagnose cancer — it indicates that further evaluation by a qualified healthcare professional is recommended.

Q: What does a negative result mean?
A: A negative result means CA-62 levels were within the normal range. In the pilot study, the negative predictive value was 100%. However, no test is perfect, and a negative result does not guarantee the absence of cancer.

Q: What is included in the $300 price?
A: The $300 price includes everything: the CA-62 test kit, certified nurse home visit, laboratory analysis in a CLIA-certified lab, and your comprehensive online wellness report. No hidden fees.

Q: Can I use my HSA or FSA to pay?
A: In many cases, yes. HSA and FSA accounts can often be used for cancer screening tests. We recommend checking with your HSA/FSA administrator.

---

## DISCLAIMERS

The CA-62 test is a wellness screening tool. It is not FDA-approved for diagnostic use. A positive result requires follow-up with a qualified healthcare professional for diagnostic confirmation. The test does not replace standard cancer screening methods recommended by healthcare providers. Pilot study results (1,005 participants) may vary in larger populations.

---

Last updated: April 2026